AFT Pharmaceuticals (ASX:AFP) has successfully registered the intravenous form of its successful ‘Maxigesic’ pain relief medication with the Therapeutic Goods Administration.
Sales of Maxigesic IV® are now expected to take place in the current financial year.
This registration clears the way for regulatory filings in other countries such as Mexico, South East Asia, Korea and the Middle East.
All these countries rely upon registration by key global reference regulators such as the TGA in Australia.
Maxigesic IV has been developed as a line extension to Maxigesic tablets, for post-operative pain relief in hospitals where patients cannot take an oral pain relief medicine.
Shares in AFT Pharmaceuticals (ASX:AFP) last traded at $3.09.